Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026
Combined company begins trading on Nasdaq at a pro forma enterprise value of approximately $288 million, marking the arrival of a new pure-play regenerative medicine and longevity platform on the U.S. public markets.
Key Facts
- Company
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Ticker
- Nasdaq: BIOT
- Announcement Date
- Category
- IR
- Source
- Official BIOT announcement
NEW YORK, NY, LAS VEGAS, NV and TOKYO, JAPAN – July 23, 2026
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (“Instinct Bio,” “BIOT,” or the “Company”), the parent company of Instinct Bio Technical Company Inc., an integrated regenerative medicine and longevity company, and Relativity Acquisition Corp. (OTC: ACQC), a special purpose acquisition company, today jointly announced the successful completion of their previously announced business combination.
The milestone positions Instinct Bio as a publicly listed life sciences company and gives U.S. investors direct access to one of the most transformative frontiers in healthcare: the science of living longer, healthier lives. Beginning on July 24, 2026, Instinct Bio’s common stock and warrants are expected to commence trading on the Nasdaq Stock Market under the ticker symbols “BIOT” and “BIOTW,” respectively.
For the full press release, please refer to the PDF below.
Full Press Release
Downloads